Expression of mitotic-arrest deficiency 2 predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer

Morishita,Masanari; Sumi,Toshiyuki; Nakano,Yusuke; Teramae,Masatomo; Fukuda,Takeshi; Nobeyama,Hiroyuki; Yoshida,Hiroyuki; Matsumoto,Yoshinari; Yasui,Tomoyo; Ishiko,Osamu

doi:10.3892/etm.2011.407

Expression of mitotic-arrest deficiency 2 predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer

Authors:
- Masanari Morishita
- Toshiyuki Sumi
- Yusuke Nakano
- Masatomo Teramae
- Takeshi Fukuda
- Hiroyuki Nobeyama
- Hiroyuki Yoshida
- Yoshinari Matsumoto
- Tomoyo Yasui
- Osamu Ishiko
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585, Japan
Published online on: December 5, 2011 https://doi.org/10.3892/etm.2011.407
Pages: 341-346

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We previously reported satisfactory therapeutic results when using cisplatin-based cyclic balloon-occluded arterial infusion chemotherapy as neoadjuvant chemotherapy (NAC), which enabled hysterectomy to be performed for patients with locally advanced cervical cancer. Mitotic arrest deficiency 2 (MAD2) is a key component of the mitotic spindle checkpoint pathway. The expression of MAD2 is associated with tumor progression and resistance to chemotherapy. Therefore, the aim of the present study was to examine whether the expression of MAD2 is related to the efficacy of NAC for locally advanced uterine cervical cancer. We reviewed 53 cases of locally advanced uterine cervical cancer (stage IIIa-IIIb; based on the International Federation of Gynecology and Obstetrics criteria). These patients were initially treated at Osaka City University Medical School Hospital, Japan, from 1995 to 2008 and were under 70 years old. Tumor samples were obtained by biopsy prior to NAC. Cases were divided into two groups: one group in which NAC was effective, surgery was possible and radiotherapy was performed (NAC+OP+R group; n=33), and another group in which NAC was ineffective and radiation therapy was performed (NAC+R group; n=20). MAD2 expression was examined in paraffin-embedded sections using the avidin-biotin peroxidase complex method. The results showed that MAD2 expression was significantly higher in the NAC+R group compared to the NAC+OP+R group (P<0.001). There was no significant difference in overall survival between the two groups, although the prognosis for the NAC+OP+R group tended to be slightly better (P=0.064). Taken together, these results suggest that the expression of MAD2 may predict the efficacy of NAC as a treatment for locally advanced uterine cervical cancer.

View Figures

View References

1.	R LiAW MurrayFeedback control of mitosis in budding yeastCell66519531199110.1016/0092-8674(81)90015-51651172
2.	Y LiR BenezraIdentification of a human mitotic checkpoint gene: hsMAD2Science274246248199610.1126/science.274.5285.2468824189
3.	A Lopez-GironaB FurnariO MondesertP RussellNuclear localization of Cdc25 is regulated by DNA damage and a 14–3–3 proteinNature39717217519999923681
4.	X WangDY JinRW NgH FengYC WongAL CheungSW TsaoSignificance of MAD2 expression to mitotic checkpoint control in ovarian cancer cellsCancer Res6216621668200211912137
5.	T Orr-WeaverRA WeinbergA checkpoint on the road to cancerNature392223224199810.1038/325209521314
6.	DS YoonRP WerstoW ZhouFJ ChrestES GarretTK KwonE GabrielsonVariable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancerAm J Pathol161391397200210.1016/S0002-9440(10)64194-612163363
7.	C LengauerKW KinzlerB VogelsteinGenetic instability in colorectal cancersNature386623627199710.1038/386623a09121588
8.	C LengauerKW KinzlerB VogelsteinGenetic instability in human cancersNature396643649199810.1038/252929872311
9.	R SotilloE HernandoE Diaz-RodriguezJ Teruya-FeldsteinC Cordon-CardoSW LoweR BenezraMad2 overexpression promotes aneuploidy and tumorigenesis in miceCancer Cell11923200710.1016/j.ccr.2006.10.01917189715
10.	AA AlizadehMB EisenRE DavisC MaIS LossosA RosenwaldJC BoldrickH SabetT TranX YuDistinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature403503511200010.1038/3500050110676951
11.	X ChenST CheungS SoST FanC BarryJ HigginsKM LaiJ JiS DudoitIO NgM Van De RijnD BotsteinPO Browngene expression patterns in human liver cancersMol Biol Cell1319291939200210.1091/mbc.02-02-0023.12058060
12.	ME GarberOG TroyanskayaK SchluensS PetersenZ ThaeslerM Pacyna-GengelbachM Van de RijnGD RosenCM PerouRI WhyteDiversity of gene expression in adenocarcinoma of the lungProc Natl Acad Sci USA981378413789200110.1073/pnas.24150079811707590
13.	GQ LiH LiHF ZhangMad2 and p53 expression profiles in colorectal cancer and its clinical significanceWorld J Gastroenterol919721975200312970887
14.	GQ LiHF ZhangMad2 and p27 expression profiles in colorectal cancer and its clinical significanceWorld J Gastroenterol1032183220200415457580
15.	SH ZhangAM XuXF ChenDH LiMP SunYJ WangClinicopathologic significance of mitotic arrest defective protein2 overexpression in hepatocellular carcinomaHum Pathol3918271834200810.1016/j.humpath.2008.06.00318715617
16.	L WangF YinY DuW DuB ChenY ZhangK WuJ DingJ LiuD FanMAD2 as a key component of mitotic checkpoint: A probable prognostic factor for gastric cancerAm J Clin Pathol131793801200910.1309/AJCPBMHHD0HFCY8W19461085
17.	K TanakaJ NishiokaK KatoA NakamuraT MouriC MikiM KusunokiT NoboriMitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancerJpn J Cancer Res92952958200110.1111/j.1349-7006.2001.tb01186.x
18.	L YuWC GuoSH ZhaoJ TangJL ChenMitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcomaAPMS118222229201010.1111/j.1600-0463.2009.02583.x20132188
19.	CW WuCW ChiTS HuangElevated level of spindle checkprotein MAD2 correlates with cellular mitotic arrest, but not with aneuploidy and clinicopathological characteristics in gastric cancerWorld J gastroenterol1032403244200415484292
20.	R SotilloJM SchvartzmanND SocciR BeneztraMad2-induced chromosome instability leads to lung tumor relapse after oncogene withdrawalNature464436440201010.1038/nature0880320173739
21.	X WangDY JinYC WongAL CheungAC ChunAK LoY LiuSW TsaoCorrelation of defective mitotic checkpoint with aberrantly reduced expression of MAD2 protein in nasopharyngeal carcinoma cellsCarcinogenesis1222932297200010.1093/carcin/21.12.229311133821
22.	MK FungHW CheungMT LingAL CheungYC WongX WangRole of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cellsBr J Cancer95475484200610.1038/sj.bjc.660328416880791
23.	HW CheungAC ChunQ WangW DengL HuXY GuanJM NichollsMT LingY Chuan WongSW TsaoDY JinX WangInactivation of human MAD2B in nasopharyngeal carcinoma cells leads to chemosensitization to DNA-damaging agentsCancer Res6643574367200610.1158/0008-5472.CAN-05-360216618761
24.	Japan Society of Gynecologic OncologyFormulation Committee of the Treatment Guidelines for Cervical Cancer2007
25.	National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology - Cervical Cancer - Version I2012
26.	M MorrisPJ EifelJ LuPW GrigsbyC LevenbackRE StevensM RotmanDM GershensonDG MutchPelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancerN Engl J Med34011371143199910.1056/NEJM19990415340150110202164
27.	PJ EifelK WinterM MorrisC LevenbackPW GrigsbyJ CooperM RotmanD GershensonDG MutchPelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01J Clin Oncol22872880200410.1200/JCO.2004.07.19714990643
28.	O IshikoT SumiT YasuiY MatsumotoN KawamuraS OgitaT KaminoK NakamuraR YamadaBalloon-occluded arterial infusion chemotherapy, simple total hysterectomy, and radiotherapy as a useful combination-therapy for advanced cancer of the uterine cervixOncol Rep71411442000
29.	JE SardiA GiaroliCE SananesN Gomez RuedaS VighiM FerreiraML BastardasG PaniceresG Di PaolaRandomized trial with neoadjuvant in stage IIIB squamous carcinoma cervix uteri: an unexpected therapeutic managementInt J Gynecol Cancer68593199610.1046/j.1525-1438.1996.06020085.x
30.	L SouhamiRA GilSE AllanPC CanaryCM AraújoLH PintoTR SilveriaA randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervixJ Clin Oncol997097719911709686
31.	MH TattersallV LorvidhayaV VootipruxA CheirsilpaF WongT AzharHP LeeSB KangA ManaloMS YenRandomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology AssociationJ Clin Oncol134444511995
32.	O IshikoT SumiT YasuiY MatsumotoS OgitaT KaminouK NakamuraR YamadaTumor marker and MR imaging criteria for evaluating the efficacy of cyclic balloon-occluded arterial infusion for advanced cancer of the uterine cervixOncol Rep4827830200010854552
33.	O IshikoT SumiH YoshidaS OgitaR YamadaExpression of apoptosis regulatory proteins in advanced cancer of the uterine cervix after cyclic balloon-occluded arterial infusion chemotherapyInt J Oncol6115111552001
34.	H NobeyamaT SumiF MisugiE OkamotoK HattoriY MatsumotoT YasuiK HondaK IwaiO IshikoAssociation of HPV infection with prognosis after neoadjuvant chemotherapy in advanced uterine cervical cancerInt J Mol Med1101105200415202023
35.	E OkamotoT SumiF MisugiH NobeyamaK HattoriH YoshidaY MatsumotoT YasuiK HondaO IshikoExpression of apoptosis-related proteins in advanced uterine cervical cancer after balloon-occluded arterial infusion chemotherapy as an indicator of the efficiency of this therapyInt J Mol Med141472005
36.	K TsujiR YamadaM KawabataK MitsuzaneM SatoM IwahashiS KitayamaR NakanoEffect of balloon occluded arterial infusion of anticancer drugs on the prognosis of cervical cancer treated with radiation therapyInt J Radiat Oncol Biol Phys3213371345199510.1016/0360-3016(94)00651-Z7635773
37.	S SironiC BelloniG TaccagniA Del MaschioInvasive cervical carcinoma: MR imaging after prospective chemotherapyRadiology180719722199110.1148/radiology.180.3.18712831871283
38.	KH KimBH LeeYS DoSY ChinBG KimStage IIb cervical carcinoma: MR evaluation of intraarterial chemotherapyRadiology1926165199410.1148/radiology.192.1.82089678208967
39.	FA SinicropeSB RuanKR ClearyLC StephensJJ LeeB LevinBcl-2 and p53 oncoprotein expression during colorectal tumorigenesisCancer Res5523724119957812951